Greenwave's 15min chart triggers bullish signal with KDJ Golden Cross, Bullish Marubozu.

The 15-minute chart for Greenwave has recently experienced a Golden Cross of the KDJ indicator, coupled with a Bullish Marubozu at 09/12/2025 13:15. This suggests a shift in momentum towards the upside, with potential for further price appreciation. The control of buyers in the market indicates a likely continuation of bullish momentum.

In the latest trading session, Pfizer (PFE) closed at $24.83, marking a +1.04% move from the previous day. This performance outpaced the S&P 500's daily gain of 0.85%, while the Dow rose by 1.36% and the tech-heavy Nasdaq appreciated by 0.72% Why Pfizer (PFE) Outpaced the Stock Market Today^[1].

Over the past month, shares of Pfizer have depreciated by 2.35%, underperforming the Medical sector's gain of 6.01% and the S&P 500's gain of 2.38%. Market participants will be closely following Pfizer's upcoming earnings report, with analysts expecting earnings of $0.79 per share, a year-over-year decline of 25.47%. Revenue is expected to be $17.18 billion, showing a 2.95% drop compared to the year-ago quarter Why Pfizer (PFE) Outpaced the Stock Market Today^[1].

For the entire year, Zacks Consensus Estimates forecast earnings of $3.13 per share and revenue of $63.81 billion, indicating changes of +0.64% and +0.29%, respectively, compared to the previous year Why Pfizer (PFE) Outpaced the Stock Market Today^[1].

Investors should also note recent changes to analyst estimates for Pfizer. Positive estimate revisions reflect optimism about the business and profitability. The Zacks Rank, an exclusive model that considers these estimated changes, currently rates Pfizer as a #3 (Hold) Why Pfizer (PFE) Outpaced the Stock Market Today^[1].

In terms of valuation, Pfizer is trading at a Forward P/E ratio of 7.86, a discount compared to its industry average Forward P/E of 14.14. The company's PEG ratio of 0.87 is also lower than the industry average of 1.57 Why Pfizer (PFE) Outpaced the Stock Market Today^[1].

The Large Cap Pharmaceuticals industry, which includes Pfizer, has a Zacks Industry Rank of 159, placing it in the bottom 36% of all 250+ industries. The Zacks Industry Rank evaluates the power of distinct industry groups by determining the average Zacks Rank of individual stocks forming the groups Why Pfizer (PFE) Outpaced the Stock Market Today^[1].